| James Graves, OD | |
|
3455 Rewak Dr, Suite 102, Fairbanks, AK 99709-5024 | |
| (907) 474-8695 | |
| (907) 474-8727 |
| Full Name | James Graves |
|---|---|
| Gender | Male |
| Speciality | Optometrist |
| Location | 3455 Rewak Dr, Fairbanks, Alaska |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1447657200 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 97 (Alaska) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| James Graves, OD 3455 Rewak Dr, Suite 102, Fairbanks, AK 99709-5024 Ph: (907) 474-8695 | James Graves, OD 3455 Rewak Dr, Suite 102, Fairbanks, AK 99709-5024 Ph: (907) 474-8695 |
News Archive
Catalyst Pharmaceutical Partners, Inc. announced today that it has signed a non-binding Letter of Intent with the National Institute on Drug Abuse (NIDA) to conduct a U.S. Phase II(b) clinical trial evaluating CPP-109, Catalyst's formulation of vigabatrin, for the treatment of cocaine addiction. It is anticipated that NIDA, under their agreement with Veteran's Administration Cooperative Studies Program, will provide substantial resources for the trial and that Catalyst will contribute approximately $2.5 million in resources as part of the estimated $10 million trial cost.
National University of Singapore researchers at the Faculty of Engineering's Department of Bioengineering have discovered a new technology that paves the way for a new safe and non-invasive method of treating deep cancer. Led by Associate Professor Zhang Yong, the team has so far, proven that their technology could inhibit tumour growth and control gene expression in mice. This is a world's first for the use of nanoparticles for non-invasive photodynamic therapy of deep cancer.
In one of the largest studies of its kind to date, researchers have found that babies born to mothers who smoke while pregnant face substantial delays in early neurological development, and the effects may be stronger than researchers had previously thought.
An international study led by the Lipids&Liver research team at the UPV/EHU-University of the Basque Country, the results of which have recently been published in the prestigious journal Cancer Research, has demonstrated that inhibiting either of the proteins E2F1 or E2F2 in the liver protects against the development of obesity-driven nonalcoholic fatty liver disease and its progression to cancer.
› Verified 2 days ago
Eye Clinic Of Fairbanks, Inc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1919 Lathrop St, Suite 103, Fairbanks, AK 99701 Phone: 907-456-7760 Fax: 907-451-7916 | |
Dr. Amanda Michelle Tompkins, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: 1717 W Cowles St, Fairbanks, AK 99701 Phone: 907-451-6682 | |
Mountain View Eye Center Optometrist Medicare: Medicare Enrolled Practice Location: 2555 Phillips Field Rd, Fairbanks, AK 99709 Phone: 907-328-2920 | |
Augusta Ann Plassmann King, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1521 Stacia St, Unit B, Fairbanks, AK 99701 Phone: 907-456-4822 | |
Anita Mullins, Optometrist Medicare: Not Enrolled in Medicare Practice Location: 201 Old Steese Hwy Ste 2, Fairbanks, AK 99701 Phone: 907-456-4822 Fax: 907-456-4830 | |
Dr. Jeremy Fulk, Optometrist Medicare: Accepting Medicare Assignments Practice Location: 116 Minnie St, Fairbanks, AK 99701 Phone: 907-456-7760 | |
John Charles Cobbett, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1867 Airport Way Ste 150a, Fairbanks, AK 99701 Phone: 907-452-2131 Fax: 907-452-2618 |